Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome

被引:2
|
作者
Kaufmann, Christoph C. [1 ,2 ]
Muthspiel, Marie [1 ,2 ]
Lunzer, Laura [1 ]
Pogran, Edita [1 ,2 ]
Zweiker, David [1 ]
Burger, Achim Leo [1 ,2 ]
Wojta, Johann [3 ,4 ,5 ]
Huber, Kurt [1 ,2 ,3 ]
机构
[1] Klin Ottakring Wilhelminenhosp, 3rd Med Dept Cardiol & Intens Care Med, A-1160 Vienna, Austria
[2] Sigmund Freud Univ, Fac Med, A-1020 Vienna, Austria
[3] Ludwig Boltzmann Inst Cardiovasc Res, A-1090 Vienna, Austria
[4] Med Univ Vienna, Core Facil, A-1090 Vienna, Austria
[5] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
关键词
acute coronary syndrome; myocardial infarction; antiplatelet therapy; anticoagulation; antithrombotic therapy; ELEVATION MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; OPEN-LABEL; TICAGRELOR MONOTHERAPY; ANTITHROMBOTIC THERAPY; CARDIOVASCULAR EVENTS; PLATELET INHIBITION; DE-ESCALATION; INTERVENTION; CLOPIDOGREL;
D O I
10.3390/jcm13082313
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] The underutilisation of dual antiplatelet therapy in acute coronary syndrome
    Anastasius, Malcolm
    Lau, Jerrett K.
    Hyun, Karice
    D'Souza, Mario
    Patel, Anushka
    Rankin, Jamie
    Walters, Darren
    Juergens, Craig
    Aliprandi-Costa, Bernadette
    Yan, Andrew T.
    Goodman, Shaun G.
    Chewj, Derek
    Brieger, David
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 240 : 30 - 36
  • [32] Double antiplatelet therapy in patients with acute coronary syndrome
    Rodionov, A. V.
    Aynetdinova, D. Kh.
    Sulimov, V. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (05): : 87 - 91
  • [33] Aggressive antiplatelet therapy before coronary stent implantation in acute coronary syndrome with essential thrombocythemia - A case report
    Fujimura, M
    Akaike, M
    Kato, M
    Takamori, N
    Abe, M
    Nishiuchi, T
    Azuma, H
    Matsumoto, T
    ANGIOLOGY, 2003, 54 (04) : 485 - 490
  • [34] Oral antiplatelet therapy in the treatment of acute coronary syndrome
    Yalcin, Ridvan
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2013, 41 : 4 - 11
  • [35] Antiplatelet and Anticoagulation Treatments in Acute Coronary Syndromes
    Nallet, O.
    Pascal, J.
    Millischer, D.
    REANIMATION, 2016, 25 (02): : 155 - 167
  • [36] Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
    Tatarunas, Vacis
    Kupstyte-Kristapone, Nora
    Zvikas, Vaidotas
    Jakstas, Valdas
    Zaliunas, Remigijus
    Lesauskaite, Vaiva
    SCIENTIFIC REPORTS, 2020, 10 (01) : 3175
  • [37] Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
    Vacis Tatarunas
    Nora Kupstyte-Kristapone
    Vaidotas Zvikas
    Valdas Jakstas
    Remigijus Zaliunas
    Vaiva Lesauskaite
    Scientific Reports, 10
  • [38] Temporal variations in ischemic and bleeding event risks after acute coronary syndrome during dual antiplatelet therapy
    Fujii, Toshiharu
    Kasai, Satoshi
    Kawamura, Yota
    Yoshimachi, Fuminobu
    Ikari, Yuji
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 392
  • [39] The Need for Novel Anticoagulation Therapy in Acute Coronary Syndrome
    Chandrasekar, Suraj
    Loomba, Rohit
    Shah, Parinda
    Arora, Rohit
    AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (01) : 61 - 66
  • [40] Antiplatelet therapy before, during, and after extremity revascularization
    Yang, Jane K.
    Jimenez, Juan Carlos
    Jabori, Sinan
    JOURNAL OF VASCULAR SURGERY, 2014, 60 (04) : 1085 - 1091